Development History



2004

Minhai Biotechnology was established.

2008

It has been reorganized with Kangtai Biological and has become a wholly owned subsidiary.

2010

Obtained a drug production license by fully introducing the human diploid cell‑based rabies vaccine technology from Sanofi Pasteur in France.

2012

China’s first: the tetravalent vaccine has obtained GMP certification, and the Hib vaccine (in vials) has also received GMP certification.

2014

In collaboration with Intravacc of the Netherlands and the WHO, an inactivated poliovirus vaccine has been introduced, and the Hib vaccine (pre-filled) has obtained GMP certification.

2017

The parent company is listed on the ChiNext Board of the Shenzhen Stock Exchange, with stock code 300601.

2020

The 23-valent pneumococcal polysaccharide vaccine has obtained a GMP certificate, the adsorbed acellular pertussis–diphtheria–tetanus combined vaccine has received registration approval, and the pentavalent vaccine has been granted a clinical trial notification.

2021

The 13-valent pneumococcal conjugate vaccine and the lyophilized Haemophilus influenzae type b conjugate vaccine have obtained registration approvals, while the inactivated COVID‑19 vaccine and the Hib vaccine (in vials) have received GMP certification (Vero cell–derived) and have been approved for emergency use.

2023

The international industrial base for next-generation vaccines has been completed and put into operation, and the lyophilized human rabies vaccine (human diploid cell–derived) has been approved for market launch.

2024

The live attenuated varicella vaccine has obtained a GMP certificate.

2025

Sabin-strain inactivated poliovirus vaccine (Vero cell) has been approved for market release.